NCT02937376 is a EARLY_PHASE1 clinical trial of N-acetyl cystein in G6PD Deficiency, sponsored by University of Thessaly.

Who is sponsoring NCT02937376?

NCT02937376 is sponsored by University of Thessaly.

What drugs are being tested in NCT02937376?

Interventions in NCT02937376: N-acetyl cystein, Placebo.

What condition does NCT02937376 study?

NCT02937376 studies G6PD Deficiency.

Is NCT02937376 still recruiting?

NCT02937376 is currently status unknown. Last updated 5 January 2022.

Last reviewed 2022-01-05 · How we verify

NCT02937376

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of N-acetyl Cystein (NAC) Supplementation in G6PD Deficient Individuals After Acute Exercise

Status unknown EARLY_PHASE1 Last updated 5 January 2022

What this trial tests

EARLY_PHASE1 trial testing N-acetyl cystein in G6PD Deficiency in 12 participants. Status unknown.

Timeline

1 February 2023

Primary endpoint
1 June 2023

1 November 2023

Quick facts

Lead sponsor	University of Thessaly
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	treatment
Enrollment	12
Start date	1 February 2023
Primary completion	1 June 2023
Estimated completion	1 November 2023
Sites	1 location across Greece

Drugs / interventions tested

N-acetyl cystein
Placebo

Conditions studied

G6PD Deficiency — all drugs for G6PD Deficiency →

Sponsor

University of Thessaly

Who can join

Adults 18 to 65, any sex, with G6PD Deficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the effects of N-acetyl Cystein (NAC) supplementation on redox status, physiological and biochemical parameters in G6PD deficient individuals after acute exercise.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for G6PD Deficiency

Currently open trials in the same condition.

NCT07468513 — Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases. · Phase 4 · recruiting

Other University of Thessaly trials

Trials by the same sponsor.

NCT07376187 — Digital Physiotherapy for Pediatric Chronic Suppurative Lung Diseases · NA · not yet recruiting
NCT07496151 — The Effectiveness of Neurodevelopmental Treatment (Bobath) and Functional Physiotherapy in Children With Cerebral Palsy. · NA · not yet recruiting
NCT07420309 — Colonoscopy TRaining With or Without Artificial INtelligence Among Endoscopy Residents · NA · recruiting
NCT07341711 — Long-term Adaptations of Skeletal Muscle After Hybrid Training. · NA · not yet recruiting
NCT07380009 — Acceptability and Adherence to Different Dosing Regimens of the Multistrain Probiotic Vivomixx® 460 Neo 9 in Adults Rece · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02937376 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Thessaly
Last refreshed: 5 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02937376.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing